18.89

0.99% -0.225

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Why IMVT Down? Discussions Forecast

Immunovant Inc stock is traded at $18.89, with a volume of 149.32K. It is down -0.99% in the last 24 hours and down -4.68% over the past month. Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Previous Close:

$19.12

Open:

$19.39

24h Volume:

149.32K

Relative Volume:

0.13

Market Cap:

$3.25B

Revenue:

Net Income/Loss:

$-323.01M

P/E Ratio:

-8.5113

EPS:

-2.22

Net Cash Flow:

$-272.30M

1W Performance:

-3.02%

1M Performance:

-4.68%

6M Performance:

-36.19%

1Y Performance:

-40.51%

1-Day Range:

$18.88

$19.60

1-Week Range:

$18.85

$20.70

52-Week Range:

$18.13

$35.97

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

917-580-3099

Address

320 WEST 37TH STREET, NEW YORK, NY

Employee

207

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMVT's Discussions on Twitter

Compare IMVT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMVT Immunovant Inc	18.93	3.25B	0	-323.01M	-272.30M	-2.22
VRTX Vertex Pharmaceuticals Inc	501.68	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	681.50	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.21	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.18	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.47	26.76B	3.32B	-860.46M	-1.04B	-8.32

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-25	Initiated	Jefferies	Hold
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform
Oct-09-24	Reiterated	Oppenheimer	Outperform
Mar-28-24	Initiated	Oppenheimer	Outperform
Mar-13-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	JP Morgan	Overweight
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Mar 12, 2025

Immunovant director Andrew Fromkin sells $156,768 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Immunovant (NASDAQ:IMVT) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World

Mar 06, 2025

Mar 05, 2025